Aaron Wall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron Wall has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Kelvin Sewell
Division of Human Molecular Immunology, Joint Research Center for Human Retrovirus Infection, Kumamoto University , 860-0811Kumamoto
2 shared publications - Anna Fuller
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom
2 shared publications - Barbara Szomolay
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XW, UK
2 shared publications - Garry Dolton
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom
2 shared publications - Hannah Thomas
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom
2 shared publications - Jade R. Hopkins
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Escape at an immunodominant SARS-CoV-2 spike epitope is not compensated by variant-specific CD8 T cells in HLA-A⁎24:02+ individuals
- 14 November 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Open AccessEscape at an immunodominant SARS-CoV-2 spike epitope is not compensated by variant-specific CD8 T cells in HLA-A⁎24:02+ individuals
- Open Access
- 2 January 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (1)
MHC-related protein 1–restricted recognition of cancer via a semi-invariant TCR-α chain
The T cell antigen presentation platform MR1 consists of 6 allomorphs in humans that differ by no more than 5 amino acids. The principal function of this highly conserved molecule involves presenting microbial metabolites to the abundant mucosal-associated invariant T (MAIT) cell subset. Recent developments suggest that the role of MR1 extends to presenting antigens from cancer cells, a function dependent on the K43 residue in the MR1 antigen binding cleft. Here, we successfully cultured cancer-activated, MR1-restricted T cells from multiple donors and confirmed that they recognized a wide range of cancer types expressing the most common MR1*01 and/or MR1*02 allomorphs (over 95% of the population), while remaining inert to healthy cells including healthy B cells and monocytes. Curiously, in all but one donor these T cells were found to incorporate a conserved TCR-α chain motif, CAXYGGSQGNLIF (where X represents 3–5 amino acids), because of pairing between 10 different TRAV genes and the TRAJ42 gene segment. This semi-invariance in the TCR-α chain is reminiscent of MAIT cells and suggests recognition of a conserved antigen bound to K43.
- 2 January 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (1)
Open AccessMHC-related protein 1–restricted recognition of cancer via a semi-invariant TCR-α chain
The T cell antigen presentation platform MR1 consists of 6 allomorphs in humans that differ by no more than 5 amino acids. The principal function of this highly conserved molecule involves presenting microbial metabolites to the abundant mucosal-associated invariant T (MAIT) cell subset. Recent developments suggest that the role of MR1 extends to presenting antigens from cancer cells, a function dependent on the K43 residue in the MR1 antigen binding cleft. Here, we successfully cultured cancer-activated, MR1-restricted T cells from multiple donors and confirmed that they recognized a wide range of cancer types expressing the most common MR1*01 and/or MR1*02 allomorphs (over 95% of the population), while remaining inert to healthy cells including healthy B cells and monocytes. Curiously, in all but one donor these T cells were found to incorporate a conserved TCR-α chain motif, CAXYGGSQGNLIF (where X represents 3–5 amino acids), because of pairing between 10 different TRAV genes and the TRAJ42 gene segment. This semi-invariance in the TCR-α chain is reminiscent of MAIT cells and suggests recognition of a conserved antigen bound to K43.
- Open Access
- 8 August 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (18)
HLA A*24:02–restricted T cell receptors cross-recognize bacterial and preproinsulin peptides in type 1 diabetes
CD8 + T cells destroy insulin-producing pancreatic β cells in type 1 diabetes through HLA class I–restricted presentation of self-antigens. Combinatorial peptide library screening was used to produce a preferred peptide recognition landscape for a patient-derived T cell receptor (TCR) that recognized the preproinsulin-derived (PPI-derived) peptide sequence LWMRLLPLL in the context of disease risk allele HLA A*24:02 . Data were used to generate a strong superagonist peptide, enabling production of an autoimmune HLA A*24:02–peptide–TCR structure by crystal seeding. TCR binding to the PPI epitope was strongly focused on peptide residues Arg4 and Leu5, with more flexibility at other positions, allowing the TCR to strongly engage many peptides derived from pathogenic bacteria. We confirmed an epitope from Klebsiella that was recognized by PPI-reactive T cells from 3 of 3 HLA A*24:02 + patients. Remarkably, the same epitope selected T cells from 7 of 8 HLA A*24 + healthy donors that cross-reacted with PPI, leading to recognition and killing of HLA A*24:02 + cells expressing PPI. These data provide a mechanism by which molecular mimicry between pathogen and self-antigens could have resulted in the breaking of self-tolerance to initiate disease.
- 8 August 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (18)
Open AccessHLA A*24:02–restricted T cell receptors cross-recognize bacterial and preproinsulin peptides in type 1 diabetes
CD8 + T cells destroy insulin-producing pancreatic β cells in type 1 diabetes through HLA class I–restricted presentation of self-antigens. Combinatorial peptide library screening was used to produce a preferred peptide recognition landscape for a patient-derived T cell receptor (TCR) that recognized the preproinsulin-derived (PPI-derived) peptide sequence LWMRLLPLL in the context of disease risk allele HLA A*24:02 . Data were used to generate a strong superagonist peptide, enabling production of an autoimmune HLA A*24:02–peptide–TCR structure by crystal seeding. TCR binding to the PPI epitope was strongly focused on peptide residues Arg4 and Leu5, with more flexibility at other positions, allowing the TCR to strongly engage many peptides derived from pathogenic bacteria. We confirmed an epitope from Klebsiella that was recognized by PPI-reactive T cells from 3 of 3 HLA A*24:02 + patients. Remarkably, the same epitope selected T cells from 7 of 8 HLA A*24 + healthy donors that cross-reacted with PPI, leading to recognition and killing of HLA A*24:02 + cells expressing PPI. These data provide a mechanism by which molecular mimicry between pathogen and self-antigens could have resulted in the breaking of self-tolerance to initiate disease.